产品
编 号：F013075
分子式：C8H14N2O2
分子量：170.21
分子式：C8H14N2O2
分子量：170.21
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
50mg
559
In-stock
100mg
880
In-stock
500mg
2400
In-stock
结构图
CAS No: 102767-28-2
产品详情
生物活性：
Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.
体内研究：
Levetiracetam (10、25 或 50 mg/kg) 抑制新生儿缺氧期间的行为和脑电图发作活动。Animal Model:Male Long-Evans rats
Dosage:10, 25, or 50?mg/kg
Administration:Intraperitoneal injection 60?min before hypoxia.
Result:Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25?mg/kg and at 50?mg/kg. Anticonvulsant activity was maximal at 50?mg/kg, at which HSs were reduced by 63.6%.
体外研究：
Levetiracetam 增加 HDAC 的转录并在 O6-甲基鸟嘌呤-DNA-甲基转移酶 (MGMT) 启动子上募集辅抑制复合物，从而沉默其活性。 Levetiracetam 使 (40 μg/mL) 多形性胶质母细胞瘤干细胞样细胞 (GSC) 对替莫唑胺 (250 μM) 处理敏感。 MGMT 表达在 Levetiracetam (40 μg/mL) 处理的 GCSCs 中下调
Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.
体内研究：
Levetiracetam (10、25 或 50 mg/kg) 抑制新生儿缺氧期间的行为和脑电图发作活动。Animal Model:Male Long-Evans rats
Dosage:10, 25, or 50?mg/kg
Administration:Intraperitoneal injection 60?min before hypoxia.
Result:Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25?mg/kg and at 50?mg/kg. Anticonvulsant activity was maximal at 50?mg/kg, at which HSs were reduced by 63.6%.
体外研究：
Levetiracetam 增加 HDAC 的转录并在 O6-甲基鸟嘌呤-DNA-甲基转移酶 (MGMT) 启动子上募集辅抑制复合物，从而沉默其活性。 Levetiracetam 使 (40 μg/mL) 多形性胶质母细胞瘤干细胞样细胞 (GSC) 对替莫唑胺 (250 μM) 处理敏感。 MGMT 表达在 Levetiracetam (40 μg/mL) 处理的 GCSCs 中下调
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备